Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2810)
All Articles published online
|
May 7, 2008 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shergill AK, Terdiman JP. Controversies in the treatment of Crohn’s disease: The case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14(17): 2670-2677 [PMID: 18461652 DOI: 10.3748/wjg.14.2670] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i17/2670.htm |
| Number | Citing Articles |
| 1 |
Veruscka Leso, Lorenzo Leggio, Alessandro Armuzzi, Giovanni Gasbarrini, Antonio Gasbarrini, Giovanni Addolorato. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. European Journal of Gastroenterology & Hepatology 2010; 22(7): 779 doi: 10.1097/MEG.0b013e328331b654
|
| 2 |
M. Baranska, R. Trzcinski, A. Dziki, M. Rychlik-Sych, M. Dudarewicz, J. Skretkowicz. The Role of N-Acetyltransferase 2 Polymorphism in the Etiopathogenesis of Inflammatory Bowel Disease. Digestive Diseases and Sciences 2011; 56(7): 2073 doi: 10.1007/s10620-010-1527-4
|
| 3 |
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeysh, M. V. Shapina, O. B. Shchukina. Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion. Almanac of Clinical Medicine 2020; 48(6): 422 doi: 10.18786/2072-0505-2020-48-050
|
| 4 |
Yoon Jae Kim, Kyung Sook Hong, Jun Won Chung, Ju Hyun Kim, Ki Baik Hahm. Prevention of Colitis-Associated Carcinogenesis with Infliximab. Cancer Prevention Research 2010; 3(10): 1314 doi: 10.1158/1940-6207.CAPR-09-0272
|
| 5 |
Austin L. Jones, Kenneth E. Jones. Crohn's disease: a case presentation. Osteopathic Family Physician 2009; 1(3): 70 doi: 10.1016/j.osfp.2009.06.007
|
| 6 |
Luca Pierelli, Sergio Rutella, Giuseppina Bonanno. Crohn’s Disease. 2010; : 131 doi: 10.1007/978-88-470-1472-5_13
|
| 7 |
Michael S. Kasparek, Andreas Bruckmeier, Florian Beigel, Mario H. Müller, Stephan Brand, Ulrich Mansmann, Karl-Walter Jauch, Thomas Ochsenkühn, Martin E. Kreis. Infliximab Does Not Affect Postoperative Complication Rates in Crohnʼs Patients Undergoing Abdominal Surgery. Inflammatory Bowel Diseases 2012; 18(7): 1207 doi: 10.1002/ibd.21860
|
| 8 |
Anuradha Pandey, Ennaliza Salazar, Christopher S. C. Kong, Wee Chian Lim, Jeannie Ong, David E. H. Ong, Christina Ong, Marion Aw, Eric Wee, Sai Wei Chuah, Valerie Tan, Wei Lin Tay, Nivedita Nadkarni, Khoon Lin Ling. Risk of Major Abdominal Surgery in an Asian Population-based Crohnʼs Disease Cohort. Inflammatory Bowel Diseases 2015; 21(11): 2625 doi: 10.1097/MIB.0000000000000525
|
| 9 |
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert W L Leong. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Journal of Gastroenterology and Hepatology 2019; 34(8): 1296 doi: 10.1111/jgh.14648
|
| 10 |
Isaiah P Schuster, Hugo Mutz, Sapphire Perera, Royce Perera, Erin Taub, Ramona Rajapakse. Influence of Pharmaceutical Direct-to-Consumer Advertisement on Medical Treatment of Inflammatory Bowel Disease—An Outpatient Survey-Based Study. Crohn's & Colitis 360 2020; 2(4) doi: 10.1093/crocol/otaa054
|
| 11 |
Lynne V McFarland. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World Journal of Gastroenterology 2008; 14(17): 2625-2629 doi: 10.3748/wjg.14.2625
|
| 12 |
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. The Lancet Gastroenterology & Hepatology 2020; 5(12): 1076 doi: 10.1016/S2468-1253(20)30299-5
|
| 13 |
Miguel Regueiro. Management and prevention of postoperative Crohnʼs disease. Inflammatory Bowel Diseases 2009; 15(10): 1583 doi: 10.1002/ibd.20909
|
| 14 |
F. BERMEJO, A. LÓPEZ‐SANROMÁN, A. ALGABA, M. VAN‐DOMSELAAR, J. P. GISBERT, S. GARCÍA‐GARZÓN, E. GARRIDO, B. PIQUERAS, G. DE LA POZA, I. GUERRA. Mercaptopurine rescue after azathioprine‐induced liver injury in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2010; 31(1): 120 doi: 10.1111/j.1365-2036.2009.04132.x
|
| 15 |
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert WL Leong. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intestinal Research 2019; 17(3): 285 doi: 10.5217/ir.2019.00026
|
| 16 |
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina, O. B. Shchukina. Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion. Modern Rheumatology Journal 2020; 14(3): 7 doi: 10.14412/1996-7012-2020-3-7-18
|
| 17 |
Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera, Mariane Christina Savio, Maria Paz Gimenez Villamil, Remo Panaccione, Siew C Ng, Gilaad G Kaplan, Paulo Gustavo Kotze. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. The Lancet Gastroenterology & Hepatology 2024; 9(3): 263 doi: 10.1016/S2468-1253(23)00284-4
|